All In Biotech

Drug Trial Radar · NCT04678453

Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)

Single Center, Open Label, Phase 1 Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Subjects With Alzheimer's Disease (AD)

Last checked: Nov 19, 2026Latest source record: Mar 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

10

Actual

Start

Jan 6, 2021

Primary completion

Aug 16, 2023

Study completion Jan 31, 2024

Sponsor

Lead sponsor
NKGen Biotech, Inc.Industry
Sponsor type
Industry
First posted
Dec 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of SNK01 (autologous natural killer cell), as a single agent, for the treatment of subjects with Alzheimer's disease.

Conditions

  • Alzheimer Disease
  • Neuro-Degenerative Disease

Interventions

  • SNK01Biological

    Patient-specific ex vivo expanded autologous natural killer cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the safety profile of SNK01 monotherapy in patients with mild cognitive impairment (MCI) or Alzheimer's Disease by monitoring for adverse events.Time frame: Up to 6 months
  2. To determine the tolerability of SNK01 monotherapy in patients with mild cognitive impairment (MCI) or Alzheimer's Disease by monitoring for adverse events.Time frame: Up to 6 months
  3. To determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of SNK01 monotherapy.Time frame: Up to 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Angeles Tijuana

    Tijuana, Estado de Baja California, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.